Holen Sie sich die Stockscreener-App
0.7298
0.38%
-0.0028
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
A drug patent runs to 2045. FDA approval may allow up to five more years. - Stock Titan
Cognition Therapeutics Stock Price Forecast. Should You Buy CGTX? - StockInvest.us
Cognition Therapeutics Schedules FDA Type C Meeting to Discuss Phase 3 Trial Endpoint for Zervimesine in Dementia with Lewy Bodies - Quiver Quantitative
An experimental drug slowed the progression of hallucinations and delusions by 89% vs. placebo. - Stock Titan
FDA aligns with Cognition on pivotal DLB psychosis trial - scanx.trade
An Alzheimer's drug will be discussed Sept. 15 by Cognition Therapeutics - Stock Titan
MU: Micron Technology Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Cognition (CGTX) Today: Moves 1.14% Lower to $0.98 for the Current Session; Technical Setup: the $0.93 to $1.03 Range Remains in Focus under the Current SnapshotIPO Entry Watch - vinanet.vn
Cognition (CGTX) Earnings Report: Reported EPS Tops Expectations; Market Reaction: Shares Move 0.22% Lower in the Latest ReadingPreliminary Results - vinanet.vn
Cognition Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Dealer Delta - vinanet.vn
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Money Flow Index - dars.gov.et
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Point of Control - careplusvn.com
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat
Cognition Therapeutics Stock (CGTX) Opinions on biotech upside speculation - Quiver Quantitative
Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cognition Therapeutics, Inc. (CGTX) latest stock news and headlines - Yahoo Finance UK
Cognition Therapeutics Inc Q2 2026: Net loss $(3.9M), EPS $(0.04) — 10-Q Summary - TradingView
Cognition Therapeutics Inc (CGTX) Stock News Today - TradingKey
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics Q2 EPS beats estimate as R&D cuts narrow losses - scanx.trade
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cognition Therapeutics reports Q2 2026 net loss $3.9M, cash $34.8M; plans Phase 3 in DLB psychosis - TradingView
Cognition Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - Yahoo Finance
Cognition plans mid-2027 dementia trial; patent could extend to 2045 - Stock Titan
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - GlobeNewswire
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cognition Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Edges Higher as Traders Eye Key Resistance LevelsAdvance Decline Volume - vinanet.vn
Cognition Therapeutics (NASDAQ:CGTX) Trading Up 3.3%Time to Buy? - MarketBeat
Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey
Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CGTX|Cognition Therapeutics Inc|Price:1.020|Chg%:-0.040 - tradingkey.com
Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey
Cognition Therapeutics Inc (CGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey
Cognition Therapeutics Inc (CGTX) Income Statement - TradingKey
Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.982|Chg%:-0.038 - TradingKey
CGTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Progress in Alzheimer’s PipelineRevenue Growth Outlook - vinanet.vn
Cognition Therapeutics (CGTX) Slips 4% as Support Level Comes Into FocusRunaway Gap - vinanet.vn
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):